T
Tuulia Hyötyläinen
Researcher at Örebro University
Publications - 271
Citations - 14986
Tuulia Hyötyläinen is an academic researcher from Örebro University. The author has contributed to research in topics: Gas chromatography & Lipidomics. The author has an hindex of 55, co-authored 247 publications receiving 11850 citations. Previous affiliations of Tuulia Hyötyläinen include University of Helsinki & Steno Diabetes Center.
Papers
More filters
Journal ArticleDOI
Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.
Sama I. Sayin,Annika Wahlström,Jenny Felin,Sirkku Jäntti,Hanns-Ulrich Marschall,Krister Bamberg,Bo Angelin,Tuulia Hyötyläinen,Matej Orešič,Fredrik Bäckhed,Fredrik Bäckhed +10 more
TL;DR: It is suggested that the gut microbiota not only regulates secondary bile acids metabolism but also inhibits bile acid synthesis in the liver by alleviating FXR inhibition in the ileum.
Journal ArticleDOI
Human gut microbes impact host serum metabolome and insulin sensitivity
Helle Krogh Pedersen,Valborg Gudmundsdottir,Henrik Nielsen,Tuulia Hyötyläinen,Tuulia Hyötyläinen,Trine G. Nielsen,Benjamin A. H. Jensen,Kristoffer Forslund,Falk Hildebrand,Falk Hildebrand,Edi Prifti,Edi Prifti,Gwen Falony,Florence Levenez,Joël Doré,Ismo Mattila,Ismo Mattila,Damian R. Plichta,Päivi Pöhö,Päivi Pöhö,Lars Hellgren,Manimozhiyan Arumugam,Shinichi Sunagawa,Sara Vieira-Silva,Torben Jørgensen,Torben Jørgensen,Jacob Bak Holm,Kajetan Trošt,Karsten Kristiansen,Susanne Brix,Jeroen Raes,Jeroen Raes,Jun Wang,Torben Hansen,Torben Hansen,Peer Bork,Søren Brunak,Søren Brunak,Matej Orešič,Matej Orešič,Matej Orešič,S. Dusko Ehrlich,S. Dusko Ehrlich,Oluf Pedersen +43 more
TL;DR: It is shown how the human gut microbiome impacts the serum metabolome and associates with insulin resistance in 277 non-diabetic Danish individuals and suggested that microbial targets may have the potential to diminish insulin resistance and reduce the incidence of common metabolic and cardiovascular disorders.
Journal ArticleDOI
The Dynamics of the Human Infant Gut Microbiome in Development and in Progression toward Type 1 Diabetes
Aleksandar Kostic,Aleksandar Kostic,Dirk Gevers,Heli Siljander,Tommi Vatanen,Tommi Vatanen,Tuulia Hyötyläinen,Tuulia Hyötyläinen,Anu-Maaria Hämäläinen,Aleksandr Peet,Vallo Tillmann,Päivi Pöhö,Päivi Pöhö,Ismo Mattila,Ismo Mattila,Harri Lähdesmäki,Eric A. Franzosa,Outi Vaarala,Marcus C. de Goffau,Hermie J. M. Harmsen,Jorma Ilonen,Jorma Ilonen,Suvi M. Virtanen,Suvi M. Virtanen,Clary B. Clish,Matej Orešič,Matej Orešič,Curtis Huttenhower,Curtis Huttenhower,Mikael Knip,Ramnik J. Xavier +30 more
TL;DR: Trends in the development of the human infant gut microbiome along with specific alterations that precede T1D onset and distinguish T2D progressors from nonprogressors are identified.
Journal ArticleDOI
Novel Theranostic Opportunities Offered by Characterization of Altered Membrane Lipid Metabolism in Breast Cancer Progression
Mika Hilvo,Carsten Denkert,Laura Lehtinen,Berit Maria Müller,Scarlet F. Brockmöller,Tuulikki Seppänen-Laakso,Jan Budczies,Elmar Bucher,Laxman Yetukuri,Sandra Castillo,Emilia Berg,Heli Nygren,Marko Sysi-Aho,Julian L. Griffin,Oliver Fiehn,Sibylle Loibl,Christiane Richter-Ehrenstein,Cornelia Radke,Tuulia Hyötyläinen,Olli Kallioniemi,Kristiina Iljin,Matej Orešič +21 more
TL;DR: Analyzing the global lipid profiles of breast cancer, integrating the results to protein expression, and validate the findings by functional experiments imply that phospholipids may have diagnostic potential as well as that modulation of their metabolism may provide therapeutic opportunities in breast cancer treatment.
Journal ArticleDOI
Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease
Panu K. Luukkonen,Panu K. Luukkonen,You Zhou,Sanja Sädevirta,Sanja Sädevirta,Marja Leivonen,Johanna Arola,Matej Orešič,Tuulia Hyötyläinen,Hannele Yki-Järvinen,Hannele Yki-Järvinen +10 more
TL;DR: Similar increases in liver fat and NASH are associated with a metabolically harmful saturated, ceramide-enriched liver lipidome in 'Metabolic NAFLD' but not in 'PNPLA3NAFLD', which may explain why metabolic but not PNPLA3 NAFLd increases the risk of type 2 diabetes and cardiovascular disease.